<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Intramuscular <z:chebi fb="0" ids="41879">dexamethasone</z:chebi> combined with intravenous low-molecular-weight <z:chebi fb="0" ids="52071">dextran</z:chebi> (<z:chebi fb="0" ids="52071">dextran 40</z:chebi>) was compared with placebo in 40 patients with <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C1262005" disease_type="Disease or Syndrome" abbrv="">ischaemic cerebral infarction</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>A double-blind procedure was used </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="41879">Dexamethasone</z:chebi> was given for up to 14 days and <z:chebi fb="0" ids="52071">dextran 40</z:chebi> for up to three days after the infarction </plain></SENT>
<SENT sid="3" pm="."><plain>A weighted scoring system was used to evaluate neurological state and mobility </plain></SENT>
<SENT sid="4" pm="."><plain>There were no differences in mortality or in improvement of the neurological or mobility scores between the two groups </plain></SENT>
</text></document>